2024 SOHN Conference Stock Pitches
We were one of the media sponsors of the 2024 Sohn Investment Conference in New York City on April 3rd and we will be sharing our takeaways with our premium subscribers over the next few days.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 5,039,957 | $179,321,670 | -2% | 2.16% |
| 2. | Point72 Asset Management Steve Cohen | 3,416,900 | $121,573,302 | -20% | 0.29% |
| 3. | EcoR1 Capital Oleg Nodelman | 2,012,517 | $71,605,355 | +32% | 1.85% |
| 4. | OrbiMed Advisors Samuel Isaly | 1,667,360 | $59,324,669 | -43% | 1.18% |
| 5. | Perceptive Advisors Joseph Edelman | 1,255,512 | $44,671,117 | -1% | 0.99% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | Director | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | Large Shareholder | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | Large Shareholder | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | Large Shareholder | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | Officer, Director | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.47 | 14,375 | 27,786 | 2024-04-15 | Filing | ||
| $49.17 | 40,951 | 237,835 | 2024-04-04 | Filing | ||
| $46.38 | 17,500 | Director | 6,000 | 2024-03-28 | Filing | |
| $45.39 | 2,359 | Officer | 52,580 | 2024-03-22 | Filing | |
| $44.22 | 30,000 | Officer | 54,939 | 2024-03-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,345,114 | $190,179,156 | 0% | |
| 2. | 4,043,865 | $143,880,730 | 0.01% | |
| 3. | 3,563,736 | $126,797,727 | 0% | |
| 4. | 3,502,452 | $124,617,243 | 0% | |
| 5. | 3,245,105 | $115,460,836 | 0.02% |
News See All
Insiders Are Dumping These 5 Healthcare Stocks
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine-related diseases.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2023 Financial Results Conference Call. At this time all participants are in listen-only mode.
12 Stocks Billionaire Steve Cohen Just Bought and Sold
In this article, we're going to take a look at 12 stocks billionaire Steve Cohen just bought and sold.
Top 10 Growth Stocks in Biotech
The biotech industry encompasses a wide range of fields, including genetic engineering, biomanufacturing, bioinformatics, and synthetic biology.
Is CRNX A Good Stock To Buy Now?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Are Piling Into Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX)
How do we determine whether Crinetics Pharmaceuticals, Inc.
Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX)
You probably know from experience that there is not as much information on small-cap companies as there is on large companies.